BGI Americas Corporation is the leading provider of genomics and proteomics services in the Americas Region as part of BGI Genomics, a public company listed on the Shenzhen Stock Exchange. Established in 2010, BGI Americas has grown to include presence in Boston and San Jose, serving a wide range of customers in genetics research, drug R&D and diagnostics. In response to the COVID-19 pandemic in 2020, BGI Americas introduced its diagnostic solutions to the north and south American markets, and initiated its in vitro diagnostics business. BGI brings 20 years of genomics experience to its customers and collaborators. We are committed to advancing genetic research, technologies and applications to benefit the mankind.